Tirzepatide
SURMOUNT-J
Eli Lilly · Phase 3 · Completed · Enrollment 267
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| 10 Milligrams (mg) Tirzepatide | n/r | n/r | n/r | n/r | n/r |
| 15 mg Tirzepatide | 18 participants | 9 participants | 7 participants | n/r | 0 |
| Placebo | 3 participants | 3 participants | 3 participants | n/r | 0 |
| 10 mg Tirzepatide | 10 participants | 5 participants | 9 participants | n/r | 0 |
A count stays a count. This page does not turn a count into a percent.